公开(公告)号：US20230242486A1

公开(公告)日：2023-08-03

申请号：US18007840

申请日：2021-05-28

Applicant: SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. ,  SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Inventor： Jianqi LI ,  Yangli QI ,  Xiaowen CHEN ,  Junwei XU ,  Ruixiang YUAN ,  Qiang PU

IPC: C07D213/74 ,  C07D213/87 ,  C07D401/04 ,  C07D405/14 ,  C07D405/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14

CPC classification number: C07D213/74 ,  C07D213/87 ,  C07D401/04 ,  C07D405/14 ,  C07D405/12 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14

Abstract: Disclosed in the present invention are a pyridinyl morpholine compound, a preparation method therefor, and an application thereof. The present invention provides a pyridinyl morpholine compound as represented by formula I, a pharmaceutically acceptable salt thereof or a hydrate of the pharmaceutically acceptable salt thereof. The compound can be used as an antagonist for one or more of D2, D3 or 5-HT2A, and is used for preparing a drug for treating schizophrenia.

公开(公告)号：US11667604B2

公开(公告)日：2023-06-06

申请号：US17627965

申请日：2020-07-14

Applicant: SHANGHAI MODERN PHARMACEUTICAL ENGINEERING RESEARCH CENTER CO., LTD. ,  SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Inventor： Jun He ,  Zhefeng Wang ,  Yuezhu Zhao ,  Yani Yang ,  Qinghui Fu ,  Wei Bian ,  Yuan Zhao ,  Chen Ge ,  Yue Zhang ,  Bing Yi ,  Minghao Niu ,  Jiuhui Zhang

IPC: C07C309/18 ,  A61K9/107 ,  A61K31/337 ,  A61K47/20 ,  A61P35/04

CPC classification number: C07C309/18 ,  A61K9/1075 ,  A61K31/337 ,  A61K47/20 ,  A61P35/04

Abstract: A phenyl-containing compound, an intermediate thereof, a preparation method therefor and an application thereof. Provided is a compound represented by formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4 and R5 are independently hydrogen, C1-C6 alkyl, C1-C6 alkoxy or C(═O)OR8; where R8 is C1-C4 alkyl; R6 is (II), (III) or (IV); and R7 is —OH, —NH2, —NHCH3, —N(CH3)2 or C1-4 alkoxy. The compound has a low critical micelle concentration (CMC) and good dilution resistance and is capable of enclosing an insoluble drug to form a small-molecule micelle having a high drug loading capacity and good stability.

公开(公告)号：US20230159463A1

公开(公告)日：2023-05-25

申请号：US17919190

申请日：2021-04-14

Applicant: SHANGHAI ZHONGZE THERAPEUTICS, CO. LTD. ,  SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Inventor： Jianqi LI ,  Zheng GUO ,  Qingwei ZHANG ,  Qiang PU ,  Zixue ZHANG ,  Minru JIAO

IPC: C07D225/06 ,  C07D267/14 ,  C07D281/10

CPC classification number: C07D225/06 ,  C07D267/14 ,  C07D281/10

Abstract: Disclosed are a benzonitric heterocyclic compound, a preparation method therefor and the use thereof. Provided in the present invention is a benzonitric heterocyclic compound represented by formula I, or a pharmaceutically acceptable salt thereof, which can be used as a histone deacetylase inhibitor, has a selective inhibitory effect on HDAC6, and has characteristics such as a high efficiency, low toxicity and ideal pharmacokinetic properties.

公开(公告)号：US09982019B2

公开(公告)日：2018-05-29

申请号：US14655830

申请日：2013-12-26

Applicant: Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory ,  Shanghai Health Creation Center Ltd. For Biopharmaceuticals R & D ,  Shanghai Institute Of Pharmaceutical Industry

Inventor： Dingfeng Zhang ,  Yuanyuan Ge ,  Mei Ge ,  Weicheng Zhou ,  Wei Wei ,  Shunli Zhang ,  Lingao Ruan ,  Zhenren Liu ,  Chang Shao

IPC: C07K9/00 ,  C07K11/00 ,  C07K14/00 ,  C07K11/02 ,  A61K38/00

CPC classification number: C07K9/006 ,  A61K38/00 ,  C07K9/008 ,  C07K11/00 ,  C07K11/02 ,  C07K14/001 ,  Y10S930/19

Abstract: The present invention provides a glycopeptide compound or pharmaceutically acceptable salt thereof as shown in Formula (I) or (II), and a method for preparing same, and pharmaceutical compositions and applications thereof, wherein the definition of R1, R2, R3, R4, R5 is the same as that of the specification. The glycopeptide compound of the present invention has in-vitro antibacterial activity and has important significance for development of new antibacterial agents.

公开(公告)号：US20150218193A1

公开(公告)日：2015-08-06

申请号：US14171228

申请日：2014-02-03

Applicant: Shanghai Institute of Pharmaceutical Industry ,  Versitech Limited

Inventor： Gui-Rong Li ,  Feng Lin

IPC: C07F9/655

CPC classification number: C07F9/65522

Abstract: Water-soluble derivatives and/or prodrugs of acacetin are described herein. The compounds can be used as cardioprotection agents against myocardial infarction induced by ischemia-reperfusion. In one embodiment the compounds are used to treat ischemic cardiac diseases. In the preferred embodiment, the compounds are used to treat and/or prevent myocardial infarction in humans.

Abstract translation: 本文描述了Acacetin的水溶性衍生物和/或前药。 该化合物可用作心肌保护剂，用于预防缺血再灌注引起的心肌梗死。 在一个实施方案中，化合物用于治疗缺血性心脏病。 在优选的实施方案中，化合物用于治疗和/或预防人心肌梗死。

公开(公告)号：US20230203095A1

公开(公告)日：2023-06-29

申请号：US17778939

申请日：2020-11-20

Applicant: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY CO., LTD. ,  CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY CO., LTD.

Inventor： Li LIU ,  Qibing MEI ,  Shumei MA ,  Liang LI ,  Nan LIU ,  Fenghua GU ,  Jiahui WANG ,  Wenqi XU

IPC: C07K7/06 ,  A61P11/06

CPC classification number: C07K7/06 ,  A61P11/06

Abstract: Provided is a biological peptide for treating lung diseases and an application thereof. Also provided is a preparation method and an application of the polypeptide, as well as a pharmaceutical composition containing the polypeptide. The polypeptide of the present invention has many advantages, such as small molecular weight, low production cost, excellent water solubility, excellent stability, long half-life, low immunogenicity, low toxic side effects, and strong tissue penetration. Moreover, the polypeptide of the present invention has significant functions of preventing, treating, and/or alleviating lung diseases such as asthma and chronic obstructive pulmonary disease.

公开(公告)号：US10508112B2

公开(公告)日：2019-12-17

申请号：US16014678

申请日：2018-06-21

Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd. ,  Shanghai Institute of Pharmaceutical Industry

Inventor： Fuli Zhang ,  Zhezhou Yang ,  Rusheng Bao ,  Weiwei Xu ,  Hua Bai

IPC: C07C237/22 ,  C07D471/04 ,  A61K31/4985 ,  C07C231/02 ,  C07C231/14

Abstract: Intermediate compounds for the preparation of Praziquantel are provided. In particular, the intermediate compounds provided include a compound of formula (IV) and a compound of formula (V). Also provided are processes for preparing the intermediate compounds. Additionally, the raw materials are inexpensive and easy to obtain, the key intermediates are easy to prepare, and the total reaction yield and purity of the obtained target compound Praziquantel is high, so that industrialized mass production of Praziquantel using the intermediate compounds is easy to achieve.

公开(公告)号：US20190177277A1

公开(公告)日：2019-06-13

申请号：US16329685

申请日：2017-08-30

Applicant: CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY ,  SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY

Inventor： Meihua XIE ,  Fuli ZHANG ,  Taizhi WU ,  Jialiang ZHONG

IPC: C07D217/18

Abstract: The present invention discloses a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL.The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL.

公开(公告)号：US10112901B2

公开(公告)日：2018-10-30

申请号：US15323709

申请日：2014-07-03

Applicant: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY ,  CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY ,  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Inventor： Yajun Guo ,  Hanbin Shan ,  Xueyan Zhu ,  Zhedong Yuan ,  Xiong Yu ,  Meng Guo ,  Mingtong Hu ,  Duzheng Wang ,  Yu Huang

IPC: C07D213/75

Abstract: Disclosed are a method for preparing a dabigatran etexilate intermediate, and an intermediate compound. The method for preparing a dabigatran etexilate intermediate 4 comprises: reacting a compound 3 with a C1-C3 alkyl alcohol solution of methylamine in an organic solvent, wherein, X=chlorine, bromine, or iodine. Also disclosed are an intermediate compound 3 and a preparation method thereof. The method for preparing a dabigatran etexilate intermediate of the present invention has the advantages of simple process, easy operation, high yield, and easy purification, thus being suitable for industrial production.

公开(公告)号：US20180297998A1

公开(公告)日：2018-10-18

申请号：US16014678

申请日：2018-06-21

Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd. ,  Shanghai Institute of Pharmaceutical Industry

Inventor： Fuli ZHANG ,  Zhezhou YANG ,  Rusheng BAO ,  Weiwei XU ,  Hua BAI

IPC: C07D471/04 ,  C07C237/22 ,  C07C231/14 ,  A61K31/4985 ,  C07C231/02

Abstract: Intermediate compounds for the preparation of Praziquantel are provided. In particular, the intermediate compounds provided include a compound of formula (IV) and a compound of formula (V). Also provided are processes for preparing the intermediate compounds. Additionally, the raw materials are inexpensive and easy to obtain, the key intermediates are easy to prepare, and the total reaction yield and purity of the obtained target compound Praziquantel is high, so that industrialized mass production of Praziquantel using the intermediate compounds is easy to achieve.